

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claim 1 (previously presented): 5-Chloro-2-(1-homopiperazinyl)-7-methylbenzoxazole or a salt thereof.

Claims 2-17 (canceled).

Claim 18 (currently amended): A ~~medicament~~ pharmaceutical composition which comprises, as an active ingredient, an effective amount of a substance selected from the group consisting of the compound according to claim 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof.

Claim 19 (currently amended): A method for the manufacture of the ~~medicament~~ pharmaceutical composition according to ~~claim 20~~ claim 18, which comprises mixing [[a]] the substance selected from the group consisting of the compound according to claim 1 5-chloro-2-(1-homopiperazinyl)-7-methylbenzoxazole, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof, with a pharmaceutical carrier.

Claim 20 (previously presented): A method for therapeutic treatment of condition of irritable bowel syndrome or digestive tract functional disorder, or condition of diarrhea, which comprises a step of administering to a mammal including human a therapeutically effective amount of a substance selected from the group consisting of the compound according to claim 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof.

AMENDMENT

U.S. Appln. No. 09/856,372

Claim 21 (previously presented): A serotonin 5-HT₃ receptor antagonistic agent for therapeutic treatment of condition of irritable bowel syndrome or digestive tract functional disorder, or condition of diarrhea, comprising as an active ingredient, an effective amount of a substance selected from the group consisting of the compound according to claim 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof.

Claim 22 (previously presented): A serotonin 5-HT₃ receptor partial activator for therapeutic treatment of condition of irritable bowel syndrome or digestive tract functional disorder, or condition of diarrhea, comprising as an active ingredient, an effective amount of a substance selected from the group consisting of the compound according to claim 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof.

Claim 23 (currently amended): An antiemetic agent, comprising a ~~serotonin 5-HT₃ receptor antagonistic agent according to claim 23~~ substance selected from the group consisting of the compound according to claim 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof.

Claim 24 (canceled).